Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Research & Development (2022 - 2025)

Historic Research & Development for Coeptis Therapeutics Holdings (COEP) over the last 4 years, with Q3 2025 value amounting to $587279.0.

  • Coeptis Therapeutics Holdings' Research & Development fell 2765.58% to $587279.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 5641.06%. This contributed to the annual value of $2.3 million for FY2024, which is 6503.51% down from last year.
  • According to the latest figures from Q3 2025, Coeptis Therapeutics Holdings' Research & Development is $587279.0, which was down 2765.58% from $290309.0 recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' Research & Development's 5-year high stood at $5.1 million during Q3 2023, with a 5-year trough of $20887.0 in Q3 2022.
  • For the 4-year period, Coeptis Therapeutics Holdings' Research & Development averaged around $832077.2, with its median value being $432723.0 (2023).
  • As far as peak fluctuations go, Coeptis Therapeutics Holdings' Research & Development skyrocketed by 2418753.77% in 2023, and later crashed by 8884.8% in 2025.
  • Coeptis Therapeutics Holdings' Research & Development (Quarter) stood at $20887.0 in 2022, then skyrocketed by 4751.57% to $1.0 million in 2023, then crashed by 66.07% to $343878.0 in 2024, then skyrocketed by 70.78% to $587279.0 in 2025.
  • Its Research & Development was $587279.0 in Q3 2025, compared to $290309.0 in Q2 2025 and $86659.0 in Q1 2025.